FindTrial
Sign In

Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients

Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-003567-31-DE
Enrollment
Unknown
Registered
2007-03-29
Start date
2007-05-25
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension metabolic syndrome MedDRA version: 9.1 Level: LLT Classification code 10020772 Term: Hypertension MedDRA version: 9.1 Level: LLT Classification code 10052066 Term: Metabolic syndrome

Interventions

Trade Name: Kinzalmono 80 mg Tabletten Product Name: Kinzalmono 80 mg Tabletten Product Code: BAY 68-9291 Pharmaceutical Form: Tablet INN or Proposed INN: TELMISARTAN CAS Number: 144701484 Concentrati

Sponsors

Med. Klinik II, Grosshadern, Klinikum der Universität München
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: age 19-60 yearsAlter 19-60 Jahre abdominal obesity (BMI > 25 kg/m² and waist circumference>=95 cm (male), >=80 cm (female)) systolic blood pressure >=130mmHg and/or diastolic blood pressure >=85mmHg Triglycerides 150-400 mg/dl Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Diabetes mellitus (fasting glucose >=126 mg/dl or antidiabetic medication) secondary causes for insulin resistence (e.g. corticosteroids) LDL-cholesterol > 190 mg/dl established atherosclerosis systolic blood pressure >=160mmHg and/or diastolic blood pressure >=100mmHg regular alcohol consumption > 30g/d contra-indications agains ARB anti-hypertensive medication lipid-lowering therapy pregnant or breast-feeding women Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and up to four weeks after the study in such a manner that the risk of pregnancy is minimized.

Design outcomes

Primary

MeasureTime frame
Main Objective: Evaluate the effect of telmisartan on inflammatory parameters in patients with hypertension.;Secondary Objective: Evaluate the effect of telmisartan on lipid parameters;Primary end point(s): Interleukin-g serum concentration—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026